Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: MOST-plus is a multicenter, randomized, open-label, adaptive Phase II trial evaluating the clinical benefit of targeted treatments matched to molecular alteration in advanced/metastatic solid tumors. Sorafenib was tested on patients with tumors harboring sorafenib-targeted genes.
Methods: The MOST-plus trial used a randomized discontinuation design. After 12 weeks of sorafenib (400 mg, po BID), patients with progressive disease discontinued study, patients with objective response were proposed to continue sorafenib, whereas patients with stable disease (SD) were randomly assigned (1:1) to the maintenance or interruption of treatment. The primary endpoint was RECIST version 1.1 progression-free rate at 16 weeks after randomization (PFR-16w). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and toxicity. Statistical analyses used a sequential Bayesian approach with interim efficacy analyses. The enrolment could be stopped in the case of a 95% probability for the estimated PFR-16w to be higher in the maintenance than in the interruption arm (NCT02029001).
Results: 151 patients were included, of whom 35 had SD at 12 weeks of Sorafenib. For the 35 patients with SD on sorafenib, the PFR-16w was 65% [95% credibility interval 43.4-83.7] in the continuation arm and 25% [7.8-48.1] in the interruption arm. Median PFS and OS were improved in the maintenance versus the interruption arm (mPFS: 5.6 [95%CI 1.97-6.77] months versus 2.0 [95%CI 1.61-3.91] months ( = 0.0231) and mOS: 14.3 [95%CI 8.9-23.8] versus 8.0 months [95%CI 3.5-15.2] ( = 0.0857)).
Conclusion: Sorafenib showed activity in progressive patients with solid tumors harboring somatic genomic alterations in sorafenib-targeted genes. Continuing sorafenib when SD is achieved improves PFR compared to interruption.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340237 | PMC |
| http://dx.doi.org/10.3390/cancers15133441 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of secondary anterior-posterior defibrillator pad placement on chest compression interruptions: a three-arm randomised manikin-based simulation study among Dutch ambulance teams.
Resusc Plus
November 2025
Helicopter Emergency Medical Service Lifeliner 3, Nijmegen, the Netherlands.
Background: Out-of-hospital cardiac arrest management prioritises effective treatment, with high-quality chest compressions and timely defibrillation being essential. While current European Resuscitation Council guidelines recommend sternal-apical defibrillator pad placement, alternative positions such as anterior-posterior (AP) are gaining interest. The integration of secondary AP pad placement with mechanical cardiopulmonary resuscitation devices (mCPR) remains underexplored.
View Article and Find Full Text PDFResponse rates, survival status and adverse events of placebo in randomized control trials for hepatocellular carcinoma: A meta-analysis.
World J Hepatol
August 2025
Department of Oncology, Shanghai Medical College, Shanghai 200032, China.
Background: In randomized controlled trials (RCTs), the placebo arm has often been ignored as the attention tends to be focused on the treatment arm. We undertook a meta-analysis based on the data from the placebo arm in RCTs of hepatocellular carcinoma (HCC), the response rates and survival status, and adverse events (AEs) were summarized and evaluated.
Aim: To systematically evaluate the response rates, survival status and AEs in the placebo arms of RCTs for HCC.
Nonstop gated CBCT for respiratory gating lung SBRT: A feasibility study.
Med Phys
September 2025
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Background: Free-breathing gated cone-beam computed tomography (gCBCT), which captures a specific anatomy coinciding with a preset gating window in the breathing cycle, is routinely prescribed to gating lung SBRT patients for pretreatment setup verification. However, a half-fan gCBCT scan can take 2-8 min (for a typical gating duty cycle of 30%-60% and patient breathing period of 3-6 s) on a C-arm linear accelerator because the gantry movement is interrupted and resumed by the respiratory gating signal multiple times over the scan. The long scan time increases patient on-table time, leading to discomfort and a higher likelihood of patient movement.
View Article and Find Full Text PDFPaclitaxel-induced Peripheral Neuropathy and Quality of Life: Sub-analysis of the MICHEL Study.
Anticancer Res
September 2025
Department of Breast and Endocrine Surgery, Institute of Medicine, University of Tsukuba, Ibaraki, Japan;
Background/aim: Paclitaxel, a taxane-class drug commonly used as part of a chemotherapy regimen for breast cancer, is causative for chemotherapy-induced peripheral neuropathy (CIPN). The MICHEL study was conducted to evaluate the efficacy of mirogabalin against CIPN which included, among its secondary endpoints, a questionnaire in which patients rated in detail the impact of their CIPN on their activities of daily living. In this study, we performed a sub-analysis for this secondary endpoint and attempted to identify acute changes that signaled CIPN.
View Article and Find Full Text PDFEchocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Exploratory Insights From the ODYSSEY-HCM Trial.
J Am Coll Cardiol
August 2025
Department of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Background: Symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM) lacks approved therapies. The ODYSSEY-HCM trial (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy; NCT05582395), the largest to date in HCM patients, evaluating the efficacy of mavacamten in symptomatic adults with nHCM, did not demonstrate improvements in its primary endpoints (functional capacity and patient-reported health status).
Objectives: This exploratory analysis of the phase 3, randomized, placebo-controlled trial evaluated echocardiographic changes in nHCM patients from baseline to week 48.